Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01919684 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01919684 is a Phase 1 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT01919684, a Phase 1 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed and fasted conditions and in subjects with Type 2 Diabetes Mellitus under fasted conditions.
Interventions
- DRUG LGD-6972
- DRUG Placebo (Captisol®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01919684
The ClinicalTrials.gov registry entry for NCT01919684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LGD-6972 is the first listed.
NCT01919684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01919684 about?
NCT01919684 is a clinical study titled "Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus". This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed and fasted conditions and in subjects with Type 2 Diabetes Mellitus unde...
What is the current status of trial NCT01919684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2013-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01919684?
The interventions under investigation include: LGD-6972 (DRUG), Placebo (Captisol®) (DRUG).
Who is sponsoring clinical trial NCT01919684?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.